Neuronetics (STIM) Cash & Equivalents (2016 - 2026)

Neuronetics (STIM) has 11 years of Cash & Equivalents data on file, last reported at $13.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 34.66% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.2 million (down 34.66% YoY) and the FY2025 annual result came in at $6.0 million, up 500.0% from the prior year.
• Cash & Equivalents grew to $13.2 million in Q1 2026 per STIM's latest filing, from $6.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $80.8 million in Q1 2022 and bottomed at $1.0 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $42.6 million (2024), against an average of $39.9 million.
• The widest annual swing landed in 2024, when Cash & Equivalents plunged 98.32%; it then soared 500.0% in 2025.
• Tracing STIM's Cash & Equivalents over 5 years: stood at $70.3 million in 2022, then dropped by 15.16% to $59.7 million in 2023, then sank by 98.32% to $1.0 million in 2024, then soared by 500.0% to $6.0 million in 2025, then soared by 120.23% to $13.2 million in 2026.
• Per Business Quant, the three latest STIM Cash & Equivalents figures stand at $13.2 million (Q1 2026), $6.0 million (Q4 2025), and $28.0 million (Q3 2025).

Peer Comparison